Brief: Xvivo Perfusion Says Evlp Business Driving Force In Q3
Oct 24 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* EVLP BUSINESS IN US WAS DRIVING FORCE THIS QUARTER
Source text for Eikon: ID:nMFN2h8knD
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength